Two Sigma Investments
CYTK icon

Two Sigma Investments’s Cytokinetics CYTK Stock Holding History

Two Sigma Investments’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.8M Buy
285,008
+10,991
+4% +$699K 0.02% 987
2025
Q4 		$17.4M Buy
+274,017
New +$17M 0.02% 795
2025
Q2 		– Sell
-44,156
Closed -$1.77M – 3237
2025
Q1 		$1.77M Sell
44,156
-47,015
-52% -$2.16M ﹤0.01% 1815
2024
Q4 		$4.29M Sell
91,171
-167,746
-65% -$8.71M 0.01% 1200
2024
Q3 		$13.7M Buy
258,917
+200,317
+342% +$11.2M 0.03% 628
2024
Q2 		$3.17M Sell
58,600
-26,745
-31% -$1.61M 0.01% 1242
2024
Q1 		$5.98M Sell
85,345
-6,495
-7% -$502K 0.01% 883
2023
Q4 		$7.67M Sell
91,840
-4,823
-5% -$175K 0.02% 786
2023
Q3 		$2.85M Buy
96,663
+54,063
+127% +$1.8M 0.01% 1182
2023
Q2 		$1.39M Sell
42,600
-172,483
-80% -$6.38M ﹤0.01% 1748
2023
Q1 		$7.57M Buy
215,083
+39,622
+23% +$1.62M 0.02% 709
2022
Q4 		$8.04M Buy
175,461
+152,910
+678% +$6.58M 0.03% 641
2022
Q3 		$1.09M Buy
+22,551
New +$1.09M ﹤0.01% 1416
2022
Q2 		– Sell
-87,325
Closed -$3.21M – 2598
2022
Q1 		$3.21M Sell
87,325
-501,416
-85% -$17.8M 0.01% 1133
2021
Q4 		$26.8M Sell
588,741
-89,833
-13% -$3.47M 0.06% 384
2021
Q3 		$24.3M Buy
678,574
+268,331
+65% +$7.9M 0.05% 397
2021
Q2 		$8.12M Sell
410,243
-135,972
-25% -$3.19M 0.02% 925
2021
Q1 		$12.7M Buy
546,215
+424,969
+351% +$9.07M 0.03% 604
2020
Q4 		$2.52M Sell
121,246
-546,828
-82% -$9.99M 0.01% 1342
2020
Q3 		$14.5M Buy
668,074
+229,286
+52% +$5.36M 0.05% 390
2020
Q2 		$10.3M Buy
438,788
+66,696
+18% +$1.25M 0.05% 380
2020
Q1 		$4.39M Sell
372,092
-90,358
-20% -$1.15M 0.04% 556
2019
Q4 		$4.91M Buy
462,450
+342,980
+287% +$3.52M 0.01% 963
2019
Q3 		$1.36M Sell
119,470
-148,745
-55% -$1.87M ﹤0.01% 1726
2019
Q2 		$3.02M Sell
268,215
-118,197
-31% -$1.14M 0.01% 1182
2019
Q1 		$3.13M Buy
386,412
+341,170
+754% +$2.51M 0.01% 1201
2018
Q4 		$286K Buy
45,242
+13,162
+41% +$96.6K ﹤0.01% 2484
2018
Q3 		$316K Sell
32,080
-34,768
-52% -$279K ﹤0.01% 2740
2018
Q2 		$555K Buy
66,848
+5,172
+8% +$43K ﹤0.01% 2577
2018
Q1 		$444K Sell
61,676
-52,226
-46% -$448K ﹤0.01% 2541
2017
Q4 		$928K Buy
113,902
+82,093
+258% +$932K ﹤0.01% 2023
2017
Q3 		$461K Sell
31,809
-86,083
-73% -$1.18M ﹤0.01% 2188
2017
Q2 		$1.43M Sell
117,892
-63,526
-35% -$883K 0.01% 1662
2017
Q1 		$2.33M Buy
181,418
+162,094
+839% +$1.89M 0.01% 1365
2016
Q4 		$235K Sell
19,324
-59,386
-75% -$630K ﹤0.01% 2867
2016
Q3 		$723K Buy
+78,710
New +$822K ﹤0.01% 2202
2016
Q2 		– Sell
-100,824
Closed -$711K – 2950
2016
Q1 		$711K Sell
100,824
-219,570
-69% -$1.6M ﹤0.01% 1817
2015
Q4 		$3.35M Buy
320,394
+280,494
+703% +$2.75M 0.02% 832
2015
Q3 		$267K Buy
39,900
+22,455
+129% +$153K ﹤0.01% 1844
2015
Q2 		$117K Buy
+17,445
New +$114K ﹤0.01% 2697
2014
Q1 		– Sell
-28,338
Closed -$185K – 2035
2013
Q4 		$185K Sell
28,338
-8,388
-23% -$55.1K ﹤0.01% 2026
2013
Q3 		$278K Buy
+36,726
New +$394K ﹤0.01% 1527

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Investments's CYTK Position: Q1 2026 in Review

Two Sigma Investments increased its Cytokinetics (CYTK) stake by 4% in Q1 2026, buying an estimated $699K and bringing the position to 285,008 shares worth $18.8M. The position accounts for 0.02% of the portfolio, ranked #987.

Two Sigma Investments first reported a position in CYTK in Q3 2013 and has held it in 42 quarters since. The position peaked at $26.8M in Q4 2021. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Two Sigma Investments held 285,008 shares of Cytokinetics worth $18.8M as of Q1 2026.
  • Two Sigma Investments bought 10,991 Cytokinetics shares in Q1 2026, an estimated $699K.
  • Cytokinetics made up 0.02% of Two Sigma Investments's portfolio in Q1 2026, its #987 holding.
  • Two Sigma Investments first reported a position in Cytokinetics in Q3 2013 and has held it in 42 quarters since.
  • Two Sigma Investments's Cytokinetics position peaked at $26.8M in Q4 2021.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.